Alcon opened higher at $72.34, compared with its previous close of $71.13. In the last trading session, the stock traded between $71.38 and $72.72. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Alcon is now worth
$ 86.10
resulting in a loss of
$ 13.90 (13.90%)
Note: Past profits do not guarantee future returns.
Rating from 13 Analysts
Today's Change
+$0.65 (+0.91%)
Day High
$72.72
Day Low
$71.38
Day Open
$72.34
Prev Close
$71.13
Volume
7,43,854
1W Return
1.61%
1M Return
9.71%
3M Return
3.07%
6M Return
-1.42%
1Y Return
-2.48%
Market Cap ($ Mn)
34,697
PE Ratio
54.55
PB Ratio
1.61
PEG Ratio
1.88
ROE
-
ROCE
4.51%
EPS (TTM)
$0.00
1 Week
1.61%
1 Month
9.71%
3 Months
3.07%
6 Months
-1.42%
9 Months
-11.55%
Alcon acquires Neurotech for $550 million to expand retina portfolio
Alcon acquired Neurotech Pharmaceuticals for **$550 million** in cash. Deal secures ENCELTO, the first FDA-approved treatment for Macular Telangiectasia Type 2. Transaction expected to be modestly accretive to net sales growth in 2027. ENCELTO currently available only in the U.S. with potential for global expansion.
9 days agoAlcon secures FDA approval for BRYTLY eye drops with 12-hour relief
FDA approves BRYTLY Redness Reliever Eye Drops for over-the-counter sale. Product delivers up to 12 hours of redness reduction with one drop. Lasts 50% longer than competitor Lumify, which offers up to 8 hours. Available at major retailers nationwide and online in coming months.
13 days agoNew Product Launches Drive Alcon's Q2 2026 Sales Growth; Full-Year Guidance Raised
Alcon delivered strong second-quarter 2026 results with net sales of $2.782 billion, up 8% on a reported basis, driven by growth across both Surgical and Vision Care segments. Core diluted EPS rose 11% to $0.84, supported by a 20.6% core operating margin. Reported results were impacted by a $402 million pre-tax non-cash charge from the discontinuation of the PowerVision IOL programs. The company raised its full-year 2026 guidance for core operating margin and core diluted EPS growth, and returned $538 million to shareholders year-to-date.
2mo agoAlcon raises FY26 adj EPS guidance to $3.44-$3.53
Alcon raises FY2026 adjusted EPS guidance to $3.44-$3.53, beating the $3.41 estimate. Sales guidance is widened to $10.835B-$11.041B versus the $11.087B estimate.
2mo agoMizuho maintains Outperform on Alcon, cuts target to $80
Mizuho analyst Anthony Petrone maintained an Outperform rating on Alcon (NYSE: ALC) while lowering the price target from $85 to $80. The move signals continued confidence in the stock despite a slightly reduced valuation outlook.
3mo agoAlcon and RxSight partner to develop adjustable PCIOLs
Alcon and RxSight have partnered to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), combining RxSight's light-adjustable technology with Alcon's optical designs. Alcon will lead commercialization, while RxSight handles development and manufacturing. RxSight receives a $60 million upfront payment, up to $140 million in milestone payments, and royalties on net sales.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $104.57 | +1.88% | $1,80,946.15M | 36.28 | |
| $448.76 | +1.03% | $1,55,559.96M | 42.73 | |
| $97.11 | +2.46% | $1,24,220.20M | 24.46 | |
| $311.75 | +2.55% | $1,19,578.88M | 34.27 | |
| $42.69 | +0.61% | $61,867.63M | 18.96 | |
| $94.44 | +2.90% | $54,435.22M | 53.70 | |
| $198.34 | +1.63% | $54,025.24M | 44.07 | |
| $252.83 | +1.06% | $35,557.76M | 23.04 | |
| $76.42 | +0.79% | $34,552.39M | 16.49 | |
| $79.93 | +1.67% | $30,162.46M | 36.04 | |
| $416.67 | +3.23% | $29,323.57M | 43.21 | |
| $32.00 | -1.14% | $28,075.23M | 89.05 |
An investment of $100 made 5 years ago in Alcon is now worth
$ 86.10
resulting in a loss of
$ 13.90 (13.90%)
Note: Past profits do not guarantee future returns.
